Magnus Jöud

Magnus Jöud

Auto-generated profile, based on publicly available information

Magnus Jöud

Hematology and Transfusion Medicine, Department of Laboratory Medicine, Lund University, Lund, Sweden

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2016 in Nature Communications
Verified
Journal Article
Open access
PDF file
JMJonathan S. Mitchell
Jonathan S. Mitchell
NLNi Li
Ni Li
NWNiels Weinhold
Niels Weinhold
AFAsta Försti
Asta Försti
MAMina Ali
Mina Ali
Richard HoulstonRichard Houlston
Richard Houlston
Multiple myeloma (MM) is a plasma cell malignancy with a significant heritable basis. Genome-wide association studies have transformed our understanding of MM predisposition, but individual studies have had limited power to discover risk loci. Here we perform a meta-analysis of these GWAS, add a new GWAS and perform replication analyses resulting in 9,866 cases and 239,188 controls. We confirm all nine known risk loci and discover eight new loci at 6p22.3 (rs34229995, P=1.31 × 10−8), 6q21 (rs9372120, P=9.09 × 10−15), 7q36.1 (rs7781265, P=9.71 × 10−9), 8q24.21 (rs1948915, P=4.20 × 10−11), 9p21.3 (rs2811710, P=1.72 × 10−13), 10p12.1 (rs2790457, P=1.77 × 10−8), 16q23.1 (rs7193541, P=5.00 × 10−12) and 20q13.13 (rs6066835, P=1.36 × 10−13), which localize in or near to JARID2, ATG5, SMARCD3, CCAT1, CDKN2A, WAC, RFWD3 and PREX1. These findings provide additional support for a polygenic model of MM and insight into the biological basis of tumour development.

16 December 2016 in Blood Advances
Verified
Journal Article
Open access
PDF file
MMMattias Möller
Mattias Möller
MJMagnus Jöud
Magnus Jöud
JSJill Rosalind Storry
Jill Rosalind Storry
MOMartin L Olsson
Martin L Olsson
Key Points: We extracted 210 412 blood group alleles (∼8.5 × 109 bp) from 1000 Genomes and matched them against official blood group reference lists. Of 1241 nonsynonymous variants found, 241 are known blood group polymorphisms while 1000 may represent undiscovered or altered antigens.

6 March 2017 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
RARam Ajore
Ram Ajore
DRDavid Raiser
David Raiser
MMMarie McConkey
Marie McConkey
MJMagnus Jöud
Magnus Jöud
BBBernd Boidol
Bernd Boidol
BNBjörn Nilsson
Björn Nilsson
Heterozygous inactivating mutations in ribosomal protein genes (RPGs) are associated with hematopoietic and developmental abnormalities, activation of p53, and altered risk of cancer in humans and model organisms. Here we performed a large‐scale analysis of cancer genome data to examine the frequency and selective pressure of RPG lesions across human cancers. We found that hemizygous RPG deletions are common, occurring in about 43% of 10,744 cancer specimens and cell lines. Consistent with p53‐dependent negative selection, such lesions are underrepresented in TP53 ‐intact tumors ( P ≪ 10 −10 ), and shRNA‐mediated knockdown of RPGs activated p53 in TP53 ‐wild‐type cells. In contrast, we did not see negative selection of RPG deletions in TP53 ‐mutant tumors. RPGs are conserved with respect to homozygous deletions, and shRNA screening data from 174 cell lines demonstrate that further suppression of hemizygously deleted RPGs inhibits cell growth. Our results establish RPG haploinsufficiency as a strikingly common vulnerability of human cancers that associates with TP53 mutations and could be targetable therapeutically.

26 May 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
BSBhairavi Swaminathan
Bhairavi Swaminathan
GTGuðmar Thorleifsson
Guðmar Thorleifsson
MJMagnus Jöud
Magnus Jöud
MAMina Ali
Mina Ali
EJEllinor Johnsson
Ellinor Johnsson
BNBjörn Nilsson
Björn Nilsson
Multiple myeloma (MM) is characterized by an uninhibited, clonal growth of plasma cells. While first-degree relatives of patients with MM show an increased risk of MM, the genetic basis of inherited MM susceptibility is incompletely understood. Here we report a genome-wide association study in the Nordic region identifying a novel MM risk locus at ELL2 (rs56219066T; odds ratio (OR)=1.25; P=9.6 × 10−10). This gene encodes a stoichiometrically limiting component of the super-elongation complex that drives secretory-specific immunoglobulin mRNA production and transcriptional regulation in plasma cells. We find that the MM risk allele harbours a Thr298Ala missense variant in an ELL2 domain required for transcription elongation. Consistent with a hypomorphic effect, we find that the MM risk allele also associates with reduced levels of immunoglobulin A (IgA) and G (IgG) in healthy subjects (P=8.6 × 10−9 and P=6.4 × 10−3, respectively) and, potentially, with an increased risk of bacterial meningitis (OR=1.30; P=0.0024).

7 April 2013 in Nature Genetics
Verified
Journal Article
Closed access
JSJill Rosalind Storry
Jill Rosalind Storry
MJMagnus Jöud
Magnus Jöud
MCMikael Kronborg Christophersen
Mikael Kronborg Christophersen
BTBritt Thuresson
Britt Thuresson
BÅBo Åkerström
Bo Åkerström
MOMartin L Olsson
Martin L Olsson

13 January 2017 in Scientific Reports
Verified
Journal Article
Open access
MCMikael K. Christophersen
Mikael K. Christophersen
MJMagnus Jöud
Magnus Jöud
RARam Ajore
Ram Ajore
SVSunitha Vege
Sunitha Vege
KLKlara W. Ljungdahl
Klara W. Ljungdahl
BNBjörn Nilsson
Björn Nilsson
The Vel blood group antigen is expressed on the red blood cells of most individuals. Recently, we described that homozygosity for inactivating mutations in SMIM1 defines the rare Vel-negative phenotype. Still, Vel-positive individuals show great variability in Vel antigen expression, creating a risk for Vel blood typing errors and transfusion reactions. We fine-mapped the regulatory region located in SMIM1 intron 2 in Swedish blood donors, and observed a strong correlation between expression and rs1175550 as well as with a previously unreported tri-nucleotide insertion (rs143702418; C > CGCA). While the two variants are tightly linked in Caucasians, we separated their effects in African Americans, and found that rs1175550G and to a lesser extent rs143702418C independently increase SMIM1 and Vel antigen expression. Gel shift and luciferase assays indicate that both variants are transcriptionally active, and we identified binding of the transcription factor TAL1 as a potential mediator of the increased expression associated with rs1175550G. Our results provide insight into the regulatory logic of Vel antigen expression, and extend the set of markers for genetic Vel blood group typing.